{"filing":{"accession_number":"0001213900-26-099018","cik":"0001505497","ticker":"BRTX","company_name":"BioRestorative Therapies, Inc.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-04","primary_document":"ea0305246-8k_biore.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1505497/000121390026099018/ea0305246-8k_biore.htm"},"events":[{"id":32863,"run_id":30210,"accession_number":"0001213900-26-099018","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Mr. Silva, Vice President of Research and Development, resigned effective immediately on September 4, 2026. Although the resignation is disputed and involves contested severance claims of approximately $1.29 million and equity acceleration, the principal disclosed action is the departure of a named officer from the Company. The Board's acknowledgment of the resignation for corporate records and the dispute over \"Good Reason\" and \"Change in Control\" do not alter the core event: an executive has left the Company.","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36150,"accession_number":"0001213900-26-099018","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Mr. Silva, Vice President of Research and Development, resigned effective immediately on September 4, 2026. Although the resignation is disputed and involves contested severance claims of approximately $1.29 million and equity acceleration, the principal disclosed action is the departure of a named officer from the Company. The Board's acknowledgment of the resignation for corporate records and the dispute over \"Good Reason\" and \"Change in Control\" do not alter the core event: an executive has left the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:30:39.262368+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36150,"accession_number":"0001213900-26-099018","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Mr. Silva, Vice President of Research and Development, resigned effective immediately on September 4, 2026. Although the resignation is disputed and involves contested severance claims of approximately $1.29 million and equity acceleration, the principal disclosed action is the departure of a named officer from the Company. The Board's acknowledgment of the resignation for corporate records and the dispute over \"Good Reason\" and \"Change in Control\" do not alter the core event: an executive has left the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:30:39.262368+00:00","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-09-11"}]}